1
|
Sesink A, Becerra M, Ruan JL, Leboucher S, Dubail M, Heinrich S, Jdey W, Petersson K, Fouillade C, Berthault N, Dutreix M, Girard PM. The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest. NAR Cancer 2024; 6:zcae011. [PMID: 38476631 PMCID: PMC10928987 DOI: 10.1093/narcan/zcae011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 02/01/2024] [Accepted: 02/27/2024] [Indexed: 03/14/2024] Open
Abstract
AsiDNA™, a cholesterol-coupled oligonucleotide mimicking double-stranded DNA breaks, was developed to sensitize tumour cells to radio- and chemotherapy. This drug acts as a decoy hijacking the DNA damage response. Previous studies have demonstrated that standalone AsiDNA™ administration is well tolerated with no additional adverse effects when combined with chemo- and/or radiotherapy. The lack of normal tissue complication encouraged further examination into the role of AsiDNA™ in normal cells. This research demonstrates the radioprotective properties of AsiDNA™. In vitro, AsiDNA™ induces a DNA-PK/p53/p21-dependent G1/S arrest in normal epithelial cells and fibroblasts that is absent in p53 deficient and proficient tumour cells. This cell cycle arrest improved survival after irradiation only in p53 proficient normal cells. Combined administration of AsiDNA™ with conventional radiotherapy in mouse models of late and early radiation toxicity resulted in decreased onset of lung fibrosis and increased intestinal crypt survival. Similar results were observed following FLASH radiotherapy in standalone or combined with AsiDNA™. Mechanisms comparable to those identified in vitro were detected both in vivo, in the intestine and ex vivo, in precision cut lung slices. Collectively, the results suggest that AsiDNA™ can partially protect healthy tissues from radiation toxicity by triggering a G1/S arrest in normal cells.
Collapse
Affiliation(s)
- Anouk Sesink
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Margaux Becerra
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Jia-Ling Ruan
- Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK
| | - Sophie Leboucher
- Histology platform, Institut Curie, CNRS UMR3348, 91405 Orsay, France
| | - Maxime Dubail
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Sophie Heinrich
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Wael Jdey
- Valerio Therapeutics, 49 Bd du Général Martial Valin, 75015 Paris, France
| | - Kristoffer Petersson
- Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK
- Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden
| | - Charles Fouillade
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Nathalie Berthault
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Marie Dutreix
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| | - Pierre-Marie Girard
- Institut Curie, Université PSL, CNRS UMR3347, INSERM U1021, 91405 Orsay, France
- Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, 91405 Orsay, France
| |
Collapse
|
2
|
Maksoud S. The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. Mol Neurobiol 2022; 59:5326-5365. [PMID: 35696013 DOI: 10.1007/s12035-022-02915-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 06/05/2022] [Indexed: 12/12/2022]
Abstract
Gliomas are the most frequent type of tumor in the central nervous system, which exhibit properties that make their treatment difficult, such as cellular infiltration, heterogeneity, and the presence of stem-like cells responsible for tumor recurrence. The response of this type of tumor to chemoradiotherapy is poor, possibly due to a higher repair activity of the genetic material, among other causes. The DNA double-strand breaks are an important type of lesion to the genetic material, which have the potential to trigger processes of cell death or cause gene aberrations that could promote tumorigenesis. This review describes how the different cellular elements regulate the formation of DNA double-strand breaks and their repair in gliomas, discussing the therapeutic potential of the induction of this type of lesion and the suppression of its repair as a control mechanism of brain tumorigenesis.
Collapse
Affiliation(s)
- Semer Maksoud
- Experimental Therapeutics and Molecular Imaging Unit, Department of Neurology, Neuro-Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
| |
Collapse
|
3
|
Liu N, Ji J, Qiu H, Shao Z, Wen X, Chen A, Yao S, Zhang X, Yao H, Zhang L. Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2020; 48:305-314. [PMID: 31858836 DOI: 10.1080/21691401.2019.1703726] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Combining DNA damage repair inhibitors and chemotherapeutic agents is an emerging strategy in cancer treatment. In this study, we engineered the polycation nanoparticle (NP), which co-encapsulated DNA damage repair inhibitor Dbait and chemotherapeutic drug Docetaxel (Dtxl), using H1 nanopolymer (folate--polyethylenimine600-cyclodextrin), and the size of H1/Dbait/Dtxl was about 117 nm. We demonstrated that H1/Dbait/Dtxl enhanced the efficiency of radio-chemotherapy in prostate cancer cells by CCK-8 assay and colony-forming assay. Importantly, the improvement of radio-chemotherapy of H1/Dbait/Dtxl in prostate cancer was also validated in vivo, and the NP did not have a high toxicity profile. The results of immunohistochemistry and western blot supported that the improved therapeutic efficacy was through inhibiting DNA damage repair signalling pathway. Our study supports further investigations using NP to co-deliver DNA damage repair inhibitors and chemotherapeutics to improve the therapeutic efficacy of cancer.
Collapse
Affiliation(s)
- Nianli Liu
- Cancer Institute of Xuzhou Medical University, Xuzhou, China
| | - Jiayin Ji
- Department of Internal Medicine, NO.731 Hospital of CASIC, Beijing, China
| | - Hui Qiu
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Zhiying Shao
- Department of Interventional Ultrasound, Zhejiang Cancer Hospital, Hangzhou, China
| | - Xin Wen
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Aoxing Chen
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Senbang Yao
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Xingying Zhang
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
| | - Hong Yao
- Cancer Institute of Xuzhou Medical University, Xuzhou, China.,Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou, China
| | - Longzhen Zhang
- Cancer Institute of Xuzhou Medical University, Xuzhou, China.,Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.,Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou, China
| |
Collapse
|
4
|
Ferreira S, Foray C, Gatto A, Larcher M, Heinrich S, Lupu M, Mispelter J, Boussin FD, Pouponnot C, Dutreix M. AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models. Clin Cancer Res 2020; 26:5735-5746. [PMID: 32900798 DOI: 10.1158/1078-0432.ccr-20-1729] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 07/08/2020] [Accepted: 08/25/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Medulloblastoma is an important cause of mortality and morbidity in pediatric oncology. Here, we investigated whether the DNA repair inhibitor, AsiDNA, could help address a significant unmet clinical need in medulloblastoma care, by improving radiotherapy efficacy without increasing radiation-associated toxicity. EXPERIMENTAL DESIGN To evaluate the brain permeability of AsiDNA upon systemic delivery, we intraperitoneally injected a fluorescence form of AsiDNA in models harboring brain tumors and in models still in development. Studies evaluated toxicity associated with combination of AsiDNA with radiation in the treatment of young developing animals at subacute levels, related to growth and development, and at chronic levels, related to brain organization and cognitive skills. Efficacy of the combination of AsiDNA with radiation was tested in two different preclinical xenografted models of high-risk medulloblastoma and in a panel of medulloblastoma cell lines from different molecular subgroups and TP53 status. Role of TP53 on the AsiDNA-mediated radiosensitization was analyzed by RNA-sequencing, DNA repair recruitment, and cell death assays. RESULTS Capable of penetrating young brain tissues, AsiDNA showed no added toxicity to radiation. Combination of AsiDNA with radiotherapy improved the survival of animal models more efficiently than increasing radiation doses. Medulloblastoma radiosensitization by AsiDNA was not restricted to a specific molecular group or status of TP53. Molecular mechanisms of AsiDNA, previously observed in adult malignancies, were conserved in pediatric models and resembled dose increase when combined with irradiation. CONCLUSIONS Our results suggest that AsiDNA is an attractive candidate to improve radiotherapy in medulloblastoma, with no indication of additional toxicity in developing brain tissues.
Collapse
Affiliation(s)
- Sofia Ferreira
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| | - Chloe Foray
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| | - Alberto Gatto
- Institut Curie, Paris Sciences et Lettres Research University, Centre National de la Recherche Scientifique, UMR3664, Equipe Labellisée Ligue contre le Cancer, Paris, France.,Sorbonne Universités, Université Pierre et Marie Curie Paris 06, Centre National de la Recherche Scientifique, UMR3664, Paris, France
| | - Magalie Larcher
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| | - Sophie Heinrich
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| | - Mihaela Lupu
- Institut Curie, Research Center, PSL Research University, CNRS UMR 9187, INSERM U 1196, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 9187, INSERM U1196, Orsay, Paris, France
| | - Joel Mispelter
- Institut Curie, Research Center, PSL Research University, CNRS UMR 9187, INSERM U 1196, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 9187, INSERM U1196, Orsay, Paris, France
| | - François D Boussin
- Université de Paris and Université Paris-Saclay, Inserm, LRP/iRCM/IBFJ CEA, UMR Stabilité Génétique Cellules Souches et Radiations, F-92265, Fontenay-aux-Roses, France
| | - Célio Pouponnot
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France.,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| | - Marie Dutreix
- Institut Curie, PSL Research University, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France. .,Institut Curie, Université Paris-Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, Paris, France
| |
Collapse
|
5
|
Biau J, Chautard E, Berthault N, de Koning L, Court F, Pereira B, Verrelle P, Dutreix M. Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models. Front Oncol 2019; 9:549. [PMID: 31275862 PMCID: PMC6593092 DOI: 10.3389/fonc.2019.00549] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 06/05/2019] [Indexed: 12/23/2022] Open
Abstract
High grade glioma relapses occur often within the irradiated volume mostly due to a high resistance to radiation therapy (RT). Dbait (which stands for DNA strand break bait) molecules mimic DSBs and trap DNA repair proteins, thereby inhibiting repair of DNA damage induced by RT. Here we evaluate the potential of Dbait to sensitize high grade glioma to RT. First, we demonstrated the radiosensitizer properties of Dbait in 6/9 tested cell lines. Then, we performed animal studies using six cell derived xenograft and five patient derived xenograft models, to show the clinical potential and applicability of combined Dbait+RT treatment for human high grade glioma. Using a RPPA approach, we showed that Phospho-H2AX/H2AX and Phospho-NBS1/NBS1 were predictive of Dbait efficacy in xenograft models. Our results provide the preclinical proof of concept that combining RT with Dbait inhibition of DNA repair could be of benefit to patients with high grade glioma.
Collapse
Affiliation(s)
- Julian Biau
- Centre de Recherche, Institut Curie, PSL Research University, Paris, France.,UMR3347, CNRS, Orsay, France.,U1021, INSERM, Orsay, France.,Research Department, Université Paris Sud, Orsay, France.,INSERM, U1240 IMoST, Université Clermont Auvergne, Clermont Ferrand, France.,Radiotherapy Department, Centre Jean Perrin, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Emmanuel Chautard
- INSERM, U1240 IMoST, Université Clermont Auvergne, Clermont Ferrand, France.,Pathology Department, Centre Jean Perrin, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Nathalie Berthault
- Centre de Recherche, Institut Curie, PSL Research University, Paris, France.,UMR3347, CNRS, Orsay, France.,U1021, INSERM, Orsay, France.,Research Department, Université Paris Sud, Orsay, France
| | - Leanne de Koning
- Laboratory of Proteomic Mass Spectrometry, Centre de Recherche, Institut Curie, Paris, France.,Department of Translational Research, Institut Curie, PSL Research University, Paris, France
| | - Frank Court
- GReD Laboratory, CNRS UMR 6293, INSERM U1103, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Bruno Pereira
- Biostatistics Department, DRCI, Clermont-Ferrand Hospital, Clermont-Ferrand, France
| | - Pierre Verrelle
- Centre de Recherche, Institut Curie, PSL Research University, Paris, France.,Radiotherapy Department, Centre Jean Perrin, Université Clermont Auvergne, Clermont-Ferrand, France.,U1196, INSERM, UMR9187, CNRS, Orsay, France.,Radiotherapy Department, Institut Curie Hospital, Paris, France
| | - Marie Dutreix
- Centre de Recherche, Institut Curie, PSL Research University, Paris, France.,UMR3347, CNRS, Orsay, France.,U1021, INSERM, Orsay, France.,Research Department, Université Paris Sud, Orsay, France
| |
Collapse
|
6
|
Jiao X, Yu Y, Meng J, He M, Zhang CJ, Geng W, Ding B, Wang Z, Ding X. Dual-targeting and microenvironment-responsive micelles as a gene delivery system to improve the sensitivity of glioma to radiotherapy. Acta Pharm Sin B 2019; 9:381-396. [PMID: 30972284 PMCID: PMC6437633 DOI: 10.1016/j.apsb.2018.12.001] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 11/12/2018] [Accepted: 11/20/2018] [Indexed: 12/18/2022] Open
Abstract
Dbait is a small double-stranded DNA molecule that has been utilized as a radiosensitizer to enhance the sensitivity of glioma to radiotherapy (RT). However, there is no effective drug delivery system to effectively overcome the blood-brain barrier (BBB). The aim of this study was to develop a gene delivery system by using the BBB and glioma dual-targeting and microenvironment-responsive micelles (ch-Kn(s-s)R8-An) to deliver Dbait into glioma for RT. Angiopep-2 can target the low-density lipoprotein receptor-related protein-1 (LRP1) that is overexpressed on brain capillary endothelial cells (BCECs) and glioma cells. In particular, due to upregulated matrix metalloproteinase 2 (MMP-2) in the tumor microenvironment, we utilized MMP-2-responsive peptides as the enzymatically degradable linkers to conjugate angiopep-2. The results showed that ch-Kn(s-s)R8-An micelles maintained a reasonable size (80-160 nm) with a moderate distribution and a decreased mean diameter from the cross-linking as well as exhibited low critical micelle concentration (CMC) with positive surface charge, ranging from 15 to 40 mV. The ch-K5(s-s)R8-An/pEGFP showed high gene transfection efficiency in vitro, improved uptake in glioma cells and good biocompatibility in vitro and in vivo. In addition, the combination of ch-K5(s-s)R8-An/Dbait with RT significantly inhibited the growth of U251 cells in vitro. Thus, ch-K5(s-s)R8-An/Dbait may prove to be a promising gene delivery system to target glioma and enhance the efficacy of RT on U251 cells.
Collapse
Key Words
- ATCC, American Type Culture Collection
- Arg, arginine
- BBB, blood–brain barrier
- BBTB, blood—brain tumor barriers
- CMC, critical micelle concentration
- Cell-penetrating peptides
- DTSSP, 3,3′-dithiobis(sulfosuccinimidylpropionate)
- DTT, dithiothreitol
- FBS, fetal bovine serum
- GBM, glioblastoma multiforme
- GSH, glutathione
- Gene delivery
- Glioma-targeting
- KnR8, cholesterol-polylysine-polyarginine peptide, n = 3, 5, 7
- Lys, lysine
- MMP-2, matrix metalloproteinase 2
- MWCO, molecular weight cutoff
- Microenvironment-responsive micelles
- PDI, polydispersity index
- PE, plating efficiency
- PEI, polyethylenimine
- RT, radiotherapy
- Radiosensitizer
- ch-Kn(s-s)R8-An, the disulfide cross-linked cholesterol-polylysine-polyarginine peptide core-shell polymer micelles modified with angiopep-2, n = 3, 5, 7
- ch-KnR8-An, the non-cross-linked cholesterol-polylysine-polyarginine peptide core-shell polymer micelles modified with angiopep-2, n = 3, 5, 7
- pDNA, plasmid DNA
Collapse
Affiliation(s)
- Xiuxiu Jiao
- Department of Pharmaceutics, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, Shanghai 200080, China
| | - Yuan Yu
- Department of Pharmaceutical Sciences, School of Pharmacy, Second Military Medical University, Shanghai 200082, China
| | - Jianxia Meng
- Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200082, China
| | - Mei He
- Department of Pharmaceutics, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, Shanghai 200080, China
| | - Charles Jian Zhang
- Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91768, USA
| | - Wenqian Geng
- Department of Pharmaceutics, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, Shanghai 200080, China
| | - Baoyue Ding
- Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing 314000, China
| | - Zhuo Wang
- Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200082, China
| | - Xueying Ding
- Department of Pharmaceutics, Shanghai General Hospital, Shanghai Jiao Tong University of Medicine, Shanghai 200080, China
| |
Collapse
|
7
|
Coquery N, Serduc R, Rémy C, Barbier EL, Lemasson B. Cluster versus ROI analysis to assess combined antiangiogenic therapy and radiotherapy in the F98 rat-glioma model. NMR IN BIOMEDICINE 2018; 31:e3933. [PMID: 29863805 DOI: 10.1002/nbm.3933] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Revised: 03/20/2018] [Accepted: 03/22/2018] [Indexed: 06/08/2023]
Abstract
For glioblastoma (GBM), current therapeutic approaches focus on the combination of several therapies, each of them individually approved for GBM or other tumor types. Many efforts are made to decipher the best sequence of treatments that would ultimately promote the most efficient tumor response. There is therefore a strong interest in developing new clinical in vivo imaging procedures that can rapidly detect treatment efficacy and allow individual modulation of the treatment. In this preclinical study, we propose to evaluate tumor tissue changes under combined therapies, tumor vascular normalization under antiangiogenic treatment followed by radiotherapy, using a voxel-based clustering approach. This approach was applied to a rat model of glioma (F98). Six MRI parameters were mapped: apparent diffusion coefficient, vessel wall permeability, cerebral blood volume fraction, cerebral blood flow, tissue oxygen saturation and vessel size index. We compared the classical region of interest (ROI)-based analysis with a cluster-based analysis. Five clusters, defined by their MRI features, were sufficient to characterize tumor progression and tumor changes during treatments. These results suggest that the cluster-based analysis was as efficient as the ROI-based analysis to assess tumor physiological changes during treatment, but also gave additional information regarding the voxels impacted by treatments and their localization within the tumor. Overall, cluster-based analysis appears to be a powerful tool for subtle monitoring of tumor changes during combined therapies.
Collapse
Affiliation(s)
- Nicolas Coquery
- Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), Grenoble, France
- Inserm, U1216, Grenoble, France
- INRA, INSERM, Université Rennes, Nutrition Metabolisms and Cancer (NuMeCan), Rennes, France
| | - Raphael Serduc
- Rayonnement synchrotron et Recherche médicale, Université Grenoble Alpes, EA, Grenoble, France
| | - Chantal Rémy
- Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), Grenoble, France
- Inserm, U1216, Grenoble, France
| | - Emmanuel Luc Barbier
- Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), Grenoble, France
- Inserm, U1216, Grenoble, France
| | - Benjamin Lemasson
- Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), Grenoble, France
- Inserm, U1216, Grenoble, France
| |
Collapse
|
8
|
Viallard C, Chezal JM, Mishellany F, Ranchon-Cole I, Pereira B, Herbette A, Besse S, Boudhraa Z, Jacquemot N, Cayre A, Miot-Noirault E, Sun JS, Dutreix M, Degoul F. Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy. Oncotarget 2017; 7:12927-36. [PMID: 26887045 PMCID: PMC4914332 DOI: 10.18632/oncotarget.7340] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Accepted: 01/24/2016] [Indexed: 01/15/2023] Open
Abstract
Radiolabelled melanin ligands offer an interesting strategy for the treatment of disseminated pigmented melanoma. One of these molecules, ICF01012 labelled with iodine 131, induced a significant slowing of melanoma growth. Here, we have explored the combination of [131I]ICF01012 with coDbait, a DNA repair inhibitor, to overcome melanoma radioresistance and increase targeted radionuclide therapy (TRT) efficacy. In human SK-Mel 3 melanoma xenograft, the addition of coDbait had a synergistic effect on tumor growth and median survival. The anti-tumor effect was additive in murine syngeneic B16Bl6 model whereas coDbait combination with [131I]ICF01012 did not increase TRT side effects in secondary pigmented tissues (e.g. hair follicles, eyes). Our results confirm that DNA lesions induced by TRT were not enhanced with coDbait association but, the presence of micronuclei and cell cycle blockade in tumor shows that coDbait acts by interrupting or delaying DNA repair. In this study, we demonstrate for the first time, the usefulness of DNA repair traps in the context of targeted radionuclide therapy.
Collapse
Affiliation(s)
- Claire Viallard
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Jean-Michel Chezal
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Florence Mishellany
- Anatomopathology Department, Centre Jean Perrin, Comprehensive Cancer Center, 63011 Clermont-Ferrand, France
| | - Isabelle Ranchon-Cole
- Clermont Université, Université d'Auvergne, UFR Pharmacie Laboratoire de Biophysique Neurosensorielle, Inserm U 1107, F-63001 Clermont-Ferrand, France
| | | | - Aurélie Herbette
- CNRS-UMR3347, INSERMU1021, Institut Curie, Université Paris Sud, Bat 110, Centre Universitaire 91405 Orsay, Cedex, France
| | - Sophie Besse
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Zied Boudhraa
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Nathalie Jacquemot
- Clermont Université, Université d'Auvergne, UFR Pharmacie Laboratoire de Biophysique Neurosensorielle, Inserm U 1107, F-63001 Clermont-Ferrand, France
| | - Anne Cayre
- Anatomopathology Department, Centre Jean Perrin, Comprehensive Cancer Center, 63011 Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | | | - Marie Dutreix
- CNRS-UMR3347, INSERMU1021, Institut Curie, Université Paris Sud, Bat 110, Centre Universitaire 91405 Orsay, Cedex, France
| | - Françoise Degoul
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| |
Collapse
|
9
|
Liu H, Cai Y, Zhang Y, Xie Y, Qiu H, Hua L, Liu X, Li Y, Lu J, Zhang L, Yu R. Development of a Hypoxic Radiosensitizer-Prodrug Liposome Delivery DNA Repair Inhibitor Dbait Combination with Radiotherapy for Glioma Therapy. Adv Healthc Mater 2017; 6. [PMID: 28371526 DOI: 10.1002/adhm.201601377] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 02/19/2017] [Indexed: 12/21/2022]
Abstract
Gliomas are highly radioresistant tumors, mainly due to hypoxia in the core region of the gliomas and efficient DNA double-strand break repair. However, the design of a radiosensitizer incorporating the two above mechanisms is difficult and has rarely been reported. Thus, this study develops a hypoxic radiosensitizer-prodrug liposome (MLP) to deliver the DNA repair inhibitor Dbait (MLP/Dbait) to achieve the simultaneous entry of radiosensitizers with two different mechanisms into the glioma. MLP/Dbait effectively sensitizes glioma cells to X-ray radiotherapy (RT). Histological and microscopic examinations of dissected brain tissue confirm that MLP effectively delivers Dbait into the glioma. Furthermore, the combination of MLP/Dbait with RT significantly inhibits growth of the glioma, as assessed by in vivo bioluminescence imaging. These findings suggest that MLP is a promising candidate as a Dbait delivery system to enhance the effect of RT on glioma, owing to the synergistic effects of the two different radiosensitizers.
Collapse
Affiliation(s)
- Hongmei Liu
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Yifan Cai
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Yafei Zhang
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Yandong Xie
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Hui Qiu
- Department of Radiation OncologyAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Cancer Institute of Xuzhou Medical University Xuzhou 221002 P. R. China
| | - Lei Hua
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Xuejiao Liu
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| | - Yuling Li
- School of Chemistry and Chemical EngineeringJiangsu Normal University Xuzhou 221116 P. R. China
| | - Jun Lu
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu ProvinceSchool of Life ScienceJiangsu Normal University Xuzhou 221116 Jiangsu Province P. R. China
| | - Longzhen Zhang
- Department of Radiation OncologyAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Cancer Institute of Xuzhou Medical University Xuzhou 221002 P. R. China
| | - Rutong Yu
- Brain HospitalAffiliated Hospital of Xuzhou Medical University Xuzhou 221000 China
- Institute of Nervous System DiseasesXuzhou Medical University Xuzhou Jiangsu 221002 P. R. China
| |
Collapse
|
10
|
Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol 2017; 27:4435-4444. [DOI: 10.1007/s00330-017-4792-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 01/11/2017] [Accepted: 03/06/2017] [Indexed: 12/15/2022]
|
11
|
Yao H, Qiu H, Shao Z, Wang G, Wang J, Yao Y, Xin Y, Zhou M, Wang AZ, Zhang L. Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 12:2261-2271. [PMID: 27389144 DOI: 10.1016/j.nano.2016.06.010] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Revised: 06/07/2016] [Accepted: 06/19/2016] [Indexed: 12/30/2022]
Abstract
Intensification of radiotherapy has been shown to improve prostate cancer (PCa) outcomes. We hypothesized that we could further improve radiotherapy efficacy through the use DNA repair inhibitors. In this study, we evaluated the use of a new class of DNA damage repair inhibitor, nanoparticle (NP) Dbait, in radiosensitization of PCa. NP Dbait was formulated using H1 nanopolymer (folate-polyethylenimine600-cyclodextrin). We demonstrated that NP Dbait was a potent radiosensitizer in vitro by colony forming assay using PCa cell lines. The result was validated in vivo using mouse xenograft models of PCa and we showed that NP Dbait significantly suppressed tumor growth and prolonged survival. Western blot, immunofluorescence and immunohistochemistry showed that NP Dbait inhibited DNA damage repair signaling pathways by mimicking DNA double-strand breaks. Our study supports further investigations of NP Dbait in improving the therapeutic efficacy of cancer radiotherapy.
Collapse
Affiliation(s)
- Hong Yao
- Cancer Institute of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Hui Qiu
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Zhiying Shao
- Cancer Institute of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Gang Wang
- Cancer Institute of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Jianshe Wang
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Yuanhu Yao
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Yong Xin
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Min Zhou
- Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - Andrew Z Wang
- Cancer Institute of Xuzhou Medical College, Xuzhou, Jiangsu, China; Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China; Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, Carolina Institute of Nanomedicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
| | - Longzhen Zhang
- Cancer Institute of Xuzhou Medical College, Xuzhou, Jiangsu, China; Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China.
| |
Collapse
|
12
|
Biau J, Devun F, Verrelle P, Dutreix M. [Dbait: An innovative concept to inhibit DNA repair and treat cancer]. Bull Cancer 2016; 103:227-35. [PMID: 26917468 DOI: 10.1016/j.bulcan.2016.01.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 01/11/2016] [Accepted: 01/12/2016] [Indexed: 12/22/2022]
Abstract
The ability of cancer cells to recognize damage and initiate DNA repair is an important mechanism for therapeutic resistance. The use of inhibitors of DNA damage repair or signaling pathways appears to provide a unique opportunity for targeting genetic differences between tumor and normal cells. In this review, we firstly describe the main DNA lesions induced by the different treatments and the pathways involved in their repair. Then we review the mechanism of action and applications of an innovative DNA repair inhibitor: Dbait (and its clinical form DT01). Dbait/DT01 consists of 32 bp deoxyribonucleotides forming an intramolecular DNA double helix that mimics DNA lesions. They act as a bait for DNA damage signaling enzymes, the polyadenyl-ribose polymerase (PARP), and the DNA-dependent kinase (DNA-PK), inducing a "false" DNA damage signal and ultimately inhibiting recruitment at the damage site of many proteins involved in double-strand break and single-strand break repair pathways. Preclinical studies have demonstrated the capacity of Dbait/DT01 to improve the efficiency of (i) chemotherapy in colorectal cancer or hepatocellular carcinoma models, (ii) radiofrequency ablative in colorectal cancer liver metastases models, and (iii) radiotherapy in xenografted mice with head & neck squamous cell carcinoma, glioblastoma and melanoma. Following this good preclinical results, we performed a first-in-human phase 1-2a study evaluating the safety and efficacy of the combination of DT01 with radiotherapy for the treatment of skin metastases of melanoma. Twenty-three patients were included. No dose-limiting toxicity was observed. An objective response was observed in 59% lesions, including 30% complete responses. This first promising clinical efficacy provides future potential interesting clinical development of Dbait/DT01 with various anticancer treatments.
Collapse
Affiliation(s)
- Julian Biau
- Centre de recherche, institut Curie, 91400 Orsay, France; Centre national de la recherche scientifique, UMR3347, Orsay, France; Institut national de la santé et de la recherche médicale, U1021, Orsay, France; Université Paris Sud, Orsay, France; Clermont université, université d'Auvergne, EA7283 CREaT, 63011 Clermont-Ferrand, France; Centre Jean-Perrin, département de radiothérapie, 58, rue Montalembert, 63011 Clermont-Ferrand, France.
| | - Flavien Devun
- Centre de recherche, institut Curie, 91400 Orsay, France; DNA Therapeutics, 91000 Evry, France
| | - Pierre Verrelle
- Centre de recherche, institut Curie, 91400 Orsay, France; Clermont université, université d'Auvergne, EA7283 CREaT, 63011 Clermont-Ferrand, France; Centre Jean-Perrin, département de radiothérapie, 58, rue Montalembert, 63011 Clermont-Ferrand, France
| | - Marie Dutreix
- Centre de recherche, institut Curie, 91400 Orsay, France; Centre national de la recherche scientifique, UMR3347, Orsay, France; Institut national de la santé et de la recherche médicale, U1021, Orsay, France; Université Paris Sud, Orsay, France
| |
Collapse
|
13
|
Herath NI, Devun F, Lienafa MC, Herbette A, Denys A, Sun JS, Dutreix M. The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. Mol Cancer Ther 2015; 15:15-22. [DOI: 10.1158/1535-7163.mct-15-0408] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Accepted: 10/14/2015] [Indexed: 11/16/2022]
|
14
|
Grillon E, Farion R, Reuveni M, Glidle A, Rémy C, Coles JA. Spatial profiles of markers of glycolysis, mitochondria, and proton pumps in a rat glioma suggest coordinated programming for proliferation. BMC Res Notes 2015; 8:207. [PMID: 26032618 PMCID: PMC4467611 DOI: 10.1186/s13104-015-1191-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Accepted: 05/20/2015] [Indexed: 02/07/2023] Open
Abstract
Background In cancer cells in vitro, the glycolytic pathway and the mitochondrial tricarboxylic acid (TCA) cycle are programmed to produce more precursor molecules, and relatively less ATP, than in differentiated cells. We address the questions of whether and where these changes occur in vivo in glioblastomas grown from C6 cells in rat brain. These gliomas show some spatial organization, notably in the upregulation of membrane proton transporters near the rim. Results We immunolabeled pairs of proteins (as well as DNA) on sections of rat brains containing gliomas, measured the profiles of fluorescence intensity on strips 200 µm wide and at least 3 mm long running perpendicular to the tumor rim, and expressed the intensity in the glioma relative to that outside. On averaged profiles, labeling of a marker of the glycolytic pathway, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was, as expected, greater in the glioma. Over distances up to 2.5 mm into the glioma, expression of a marker of the TCA cycle, Tom20, a pre-protein receptor on the translocation complex of the mitochondrial outer membrane, was also upregulated. The ratio of upregulation of Tom20 to upregulation of GAPDH was, on average, slightly greater than one. Near the rim (0.4–0.8 mm), GAPDH was expressed less and there was a peak in the mean ratio of 1.16, SEM = 0.001, N = 16 pairs of profiles. An antibody to V-ATPase, which, by pumping protons into vacuoles contributes to cell growth, also indicated upregulation by about 40%. When compared directly with GAPDH, upregulation of V-ATPase was only 0.764, SD = 0.016 of GAPDH upregulation. Conclusions Although there was considerable variation between individual measured profiles, on average, markers of the glycolytic pathway, of mitochondria, and of cell proliferation showed coherent upregulation in C6 gliomas. There is a zone, close to the rim, where mitochondrial presence is upregulated more than the glycolytic pathway, in agreement with earlier suggestions that lactate is taken up by cells near the rim. Electronic supplementary material The online version of this article (doi:10.1186/s13104-015-1191-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Emmanuelle Grillon
- Université Grenoble Alpes, IRMaGe, 3800, Grenoble, France. .,Inserm, US 17, 3800, Grenoble, France. .,CNRS, UMS 3552, 3800, Grenoble, France. .,CHU de Grenoble, Hopital Michallon, IRMaGe, 3800, Grenoble, France.
| | - Régine Farion
- Université Grenoble Alpes, IRMaGe, 3800, Grenoble, France. .,Inserm, US 17, 3800, Grenoble, France. .,CNRS, UMS 3552, 3800, Grenoble, France. .,CHU de Grenoble, Hopital Michallon, IRMaGe, 3800, Grenoble, France.
| | - Moshe Reuveni
- Institute of Plant Sciences, The Volcan Center, Bet Dagan, Israel.
| | - Andrew Glidle
- Department of Engineering, University of Glasgow, Glasgow, UK.
| | - Chantal Rémy
- Université Grenoble Alpes, IRMaGe, 3800, Grenoble, France. .,Inserm, U 836, 3800, Grenoble, France.
| | - Jonathan A Coles
- Institute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow, G12 8TA, UK.
| |
Collapse
|
15
|
Troprès I, Pannetier N, Grand S, Lemasson B, Moisan A, Péoc'h M, Rémy C, Barbier EL. Imaging the microvessel caliber and density: Principles and applications of microvascular MRI. Magn Reson Med 2014; 73:325-41. [DOI: 10.1002/mrm.25396] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Revised: 07/08/2014] [Accepted: 07/11/2014] [Indexed: 12/22/2022]
Affiliation(s)
- Irène Troprès
- IRMaGe; Université Grenoble Alpes; Grenoble France
- UMS 3552; CNRS; Grenoble France
- US 017; INSERM; Grenoble France
- IRMaGe, Hôpital Michallon; Centre Hospitalier Universitaire de Grenoble; Grenoble France
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France. INSERM; U836 Grenoble France
| | - Nicolas Pannetier
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
| | - Sylvie Grand
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
- CLUNI, Hôpital Michallon; Centre Hospitalier Universitaire de Grenoble; Grenoble France
| | - Benjamin Lemasson
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
| | - Anaïck Moisan
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
| | - Michel Péoc'h
- Service d'anatomo-pathologie; Centre Hospitalier Universitaire de Saint Etienne; Saint-Etienne France
- EA 2521; Université Jean Monnet; Saint-Etienne France
| | - Chantal Rémy
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
| | - Emmanuel L. Barbier
- Université Joseph Fourier; Grenoble Institut des Neurosciences; Grenoble France
- INSERM; U836 Grenoble France
| |
Collapse
|
16
|
Coquery N, Francois O, Lemasson B, Debacker C, Farion R, Rémy C, Barbier EL. Microvascular MRI and unsupervised clustering yields histology-resembling images in two rat models of glioma. J Cereb Blood Flow Metab 2014; 34:1354-62. [PMID: 24849664 PMCID: PMC4126096 DOI: 10.1038/jcbfm.2014.90] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Revised: 04/22/2014] [Accepted: 04/24/2014] [Indexed: 01/05/2023]
Abstract
Imaging heterogeneous cancer lesions is a real challenge. For diagnosis, histology often remains the reference, but it is widely acknowledged that biopsies are not reliable. There is thus a strong interest in establishing a link between clinical in vivo imaging and the biologic properties of tissues. In this study, we propose to construct histology-resembling images based on tissue microvascularization, a magnetic resonance imaging (MRI) accessible source of contrast. To integrate the large amount of information collected with microvascular MRI, we combined a manual delineation of a spatial region of interest with an unsupervised, model-based cluster analysis (Mclust). This approach was applied to two rat models of glioma (C6 and F98). Six MRI parameters were mapped: apparent diffusion coefficient, vessel wall permeability, cerebral blood volume fraction, cerebral blood flow, tissular oxygen saturation, and cerebral metabolic rate of oxygen. Five clusters, defined by their MRI features, were found to correspond to specific histologic features, and revealed intratumoral spatial structures. These results suggest that the presence of a cluster within a tumor can be used to assess the presence of a tissue type. In addition, the cluster composition, i.e., a signature of the intratumoral structure, could be used to characterize tumor models as histology does.
Collapse
Affiliation(s)
- Nicolas Coquery
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France
| | - Olivier Francois
- 1] Université Joseph Fourier, Grenoble, France [2] CNRS, UMR5525, TIMC-IMAG Laboratory, La Tronche, France
| | - Benjamin Lemasson
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France
| | - Clément Debacker
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France [3] Bruker Biospin MRI, Wissembourg, France
| | - Régine Farion
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France
| | - Chantal Rémy
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France
| | - Emmanuel Luc Barbier
- 1] INSERM, U836, Grenoble, France [2] Université Joseph Fourier, Grenoble, France
| |
Collapse
|
17
|
Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol 2012; 22:22-35. [PMID: 23270946 DOI: 10.1016/j.suronc.2012.11.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2012] [Revised: 11/03/2012] [Accepted: 11/10/2012] [Indexed: 02/07/2023]
Abstract
BACKGROUND The precise contribution of IORT to the management of locally advanced and recurrent colorectal cancer (CRC) remains uncertain. We performed a systematic review and meta-analysis to assess the value of IORT in this setting. METHODS Studies published between 1965 and 2011 that reported outcomes after IORT for advanced or recurrent CRC were identified by an electronic literature search. Studies were assessed for methodological quality and design, and evaluated for technique of IORT delivery, oncological outcomes, and complications following IORT. Outcomes were analysed with fixed-effect and random-effect model meta-analyses and heterogeneity and publication bias examined. RESULTS 29 studies comprising 14 prospective and 15 retrospective studies met the inclusion criteria and were assessed, yielding a total of 3003 patients. The indication for IORT was locally advanced disease in 1792 patients and locally recurrent disease in 1211 patients. Despite heterogeneity in methodology and reporting practice, IORT is principally applied for the treatment of close or positive margins. When comparative studies were evaluated, a significant effect favouring improved local control (OR 0.22; 95% CI = 0.05-0.86; p = 0.03), disease free survival (HR 0.51; 95% CI = 0.31-0.85; p = 0.009), and overall survival (HR 0.33; 95% CI = 0.2-0.54; p = 0.001) was noted with no increase in total (OR 1.13; 95% CI = 0.77-1.65; p = 0.57), urologic (OR 1.35; 95% CI = 0.84-2.82; p = 0.47), or anastomotic complications (OR 0.94; 95% CI = 0.42-2.1; p = 0.98). Increased wound complications were noted after IORT (OR 1.86; 95% CI = 1.03-3.38; p = 0.049). CONCLUSIONS Despite methodological weaknesses in the studies evaluated, our results suggest that IORT may improve oncological outcomes in advanced and recurrent CRC.
Collapse
|